Survodutide Heart Safety Trial: What the Results Show
- 9 views
- 0 likes
- 0 comments
- All languages combined

Sign in and earn +30 points by reading this
Read to the end, wait a few seconds, then tap the claim button below.
In short
As of 13 November 2026, the SYNCHRONIZE-CVOT trial, published online in The Lancet on 9 November, found that the obesity drug survodutide did not increase major cardiovascular events compared with placebo in 5,530 randomised adults at raised heart risk [1][2]. It is a safety result, not proof of heart benefit, and the drug is unapproved [1][2].
Key takeaways
- SYNCHRONIZE-CVOT tested once-weekly survodutide, a glucagon/GLP-1 dual agonist from Boehringer Ingelheim, against placebo in 5,530 randomised adults with obesity or overweight and heart, kidney or metabolic risks [1][2].
- The main heart and stroke composite occurred in 3.7% on survodutide and 4.1% on placebo, a hazard ratio of 0.89 (95% CI 0.67 to 1.18), meeting the trial's non-inferiority goal [1].
- Because the confidence interval crosses 1, the trial shows no increase in risk, not a reduction [1].
- Nausea affected about 48% to 49% of people on survodutide versus 12.1% on placebo, and about 1 in 5 stopped treatment because of digestive side effects [1].
- Weight loss was up to 13.7% at 72 weeks versus 2.0% with placebo under the company's supplementary analysis [2].
- Boehringer states survodutide has not been approved for use; it plans regulatory submissions for obesity, aiming to file within the next year, according to Fierce Biotech [2][4].
On this page 11 sections
- What is survodutide?
- What did the SYNCHRONIZE-CVOT trial find?
- Does survodutide protect the heart?
- Why do obesity drugs need heart safety trials?
- Who was in the survodutide trial?
- What are the side effects of survodutide?
- When could survodutide be approved?
- Common mistakes
- Frequently asked questions
- Glossary
- Sources
What is survodutide?
Survodutide (BI 456906) is an investigational once-weekly injection that activates both the glucagon receptor and the GLP-1 receptor; it is being developed by Boehringer Ingelheim for obesity and liver disease; Boehringer states it has not been approved for use [2]. The Lancet paper describes it as a dual agonist that improved markers of cardiometabolic health [1].
- How it is meant to work: Boehringer says GLP-1 receptor activity helps regulate appetite and energy intake, while glucagon receptor activity is associated with effects on energy expenditure and liver metabolism [2].
- Licensing: the drug is licensed to Boehringer from Zealand Pharma, with Boehringer responsible for development and commercialisation [2].
- Status: Boehringer states that survodutide's "efficacy and safety have not been established" [2].
- Liver disease: the US FDA granted it Breakthrough Therapy designation in September 2024 for MASH with moderate or advanced liver fibrosis, according to the company [2].
The Lancet authors note that cardiovascular safety for this new class had not yet been established before this trial [1].
WHO estimates that 1 in 7 people worldwide, about 1.1 billion, were living with obesity in 2024, and links obesity to type 2 diabetes, cardiovascular disease, liver and kidney disease and several cancers [5].
What did the SYNCHRONIZE-CVOT trial find?
The primary composite of cardiovascular death, non-fatal stroke, non-fatal heart attack, ischaemia-related coronary revascularisation or heart failure event occurred in 136 of 3,671 people (3.7%) on survodutide and 76 of 1,836 (4.1%) on placebo [1].
- Hazard ratio: 0.89 (95% CI 0.67 to 1.18), with p<0.0001 for non-inferiority [1].
- Safety margin: the trial was designed to rule out an upper confidence limit above 1.65; the observed upper limit was 1.18 [1].
- Three-part MACE (cardiovascular death, stroke or heart attack): hazard ratio 0.84 (95% CI 0.60 to 1.18), also non-inferior, according to Boehringer [2].
- Blood pressure: systolic pressure fell by up to 6.68 mmHg versus 1.76 mmHg on placebo at 72 weeks, using the company's supplementary estimand [2].
- Waist: waist circumference fell by up to 11.96 cm versus 2.74 cm on placebo [2].
- Weight: up to 13.7% weight loss at week 72 versus 2.0% on placebo [2].
The supplementary estimand estimates the effect with continued treatment, assuming no one stopped, so it tends to show larger effects than the treatment-regimen analysis used for the primary result [2]. Boehringer also reports reductions in the inflammatory marker hs-CRP and in triglycerides [2].
The table below sets out the main figures.
Does survodutide protect the heart?
No such claim can be made from this trial: it was a cardiovascular safety study designed to show survodutide does not raise heart risk, and the result is consistent with no difference from placebo [1].
The Lancet authors conclude that survodutide "was not associated with increased risk" for the primary composite, and describe the trial as providing reassuring data on cardiovascular risk [1].
- Why not a benefit: the hazard ratio of 0.89 has a confidence interval from 0.67 to 1.18, which includes 1, meaning no statistically demonstrated reduction [1].
- Event-driven design: the trial targeted 189 primary endpoint events, enough to test safety but not designed to prove benefit [1].
- Duration: median time in the study was 22.0 months [1].
- Treatment adherence: 56.0% (3.6 mg), 56.6% (6.0 mg) and 59.0% (placebo) remained on treatment until study closeout [1].
Principal investigator Biykem Bozkurt said in the company's release that the data help give "confidence in how we could manage obesity and related cardiometabolic risk" [2]. That is the investigator's view, published by the manufacturer [2].
Online summaries often turn a safety finding into a claim of protection; AI chatbots can make the same leap, as explained in AI Hallucinations Explained: Why Chatbots Make Things Up and How to Get Accurate Answers.
Why do obesity drugs need heart safety trials?
The Lancet authors write that survodutide had improved markers of cardiometabolic health, but that cardiovascular safety for this new class of glucagon/GLP-1 dual agonists had not been established, which is what this trial set out to test [1].
- A regulator commitment: Neerja Balachander of Boehringer told Fierce Biotech the company launched the study as part of its "commitment to healthcare authorities" to provide a well-rounded data package [4].
- Metabolic markers: she said the company agreed to report a panel of metabolic markers alongside heart events, and that the data turned out "a more compelling story than we had at the outset" [4].
- Muscle claims: Balachander also told Fierce the drug is aimed at people who want to lose fat "and want to conserve muscle" [4]. That is a company claim; SYNCHRONIZE-CVOT did not report body composition in its published abstract [1].
- Scale of the problem: WHO says adult obesity worldwide has more than doubled since 1990, and that in 2024, 2.6 billion adults, 45% of all adults, were overweight [5].
WHO adds that obesity is diagnosed using BMI, and that other measures such as waist circumference can also be used [5]. Waist circumference was one of the trial's key secondary endpoints [2].
Who was in the survodutide trial?
The trial randomised 5,530 adults at 524 sites in 34 countries, with a BMI of 27 or more and either established cardiovascular disease or at least two obesity complications or cardiovascular risk factors [1].
- Kidney disease: people with chronic kidney disease could join if their BMI was 30 or more [1].
- Groups: 1:1:1 randomisation; of the 5,507 who received at least one dose, 1,836 received survodutide up-titrated to 3.6 mg, 1,835 to 6.0 mg, and 1,836 placebo, each as a weekly injection [1].
- Sex: 39.8% were female and 60.2% male [1].
- Ethnicity: 78.7% were White, which may limit how far the results apply to other groups [1].
- Dates: screening ran from 20 November 2023 to 8 November 2024 [1]; the registry lists the study as completed on 30 June 2026 [3].
- Funding: the trial was funded by Boehringer Ingelheim [1].
The trial is registered as NCT06077864 on ClinicalTrials.gov, where its official title describes a phase 3, randomised, double-blind, event-driven cardiovascular safety study [3].
What are the side effects of survodutide?
Digestive side effects were common: nausea occurred in 48.0% (3.6 mg) and 49.0% (6.0 mg) of participants versus 12.1% on placebo, and vomiting in 31.7% and 34.0% versus 4.8% [1].
- Stopping because of digestive effects: 19.3% (3.6 mg) and 20.8% (6.0 mg) versus 1.9% on placebo [1].
- Any adverse event: 93.0% and 93.1% versus 85.6% [1].
- Serious adverse events: similar across groups, 22.5% and 20.8% versus 23.9% [1].
- Deaths from adverse events: 0.9% in each survodutide group versus 0.6% on placebo, which the Lancet abstract describes as primarily due to cardiac disorders [1].
Boehringer says discontinuations usually happened during dose escalation because the original protocol allowed little flexibility to slow titration or pause treatment [2]. It says newer trials, including SYNCHRONIZE-START, allow more flexible titration [2].
Neerja Balachander of Boehringer told Fierce Biotech she was "very confident" tolerability would improve in trials where clinicians can adjust doses [4]. Fierce noted that the discontinuation rate compares poorly with approved obesity drugs, while warning about cross-trial comparisons [4].
This is not medical advice. Decisions about your own treatment belong with a qualified clinician who knows your history.
When could survodutide be approved?
No approval date exists: Boehringer says it is moving forward with global regulatory submissions in obesity, and a company executive told Fierce Biotech it aims to file "at some time in the next year" [2][4].
- Other trials: SYNCHRONIZE-1 (adults without diabetes), SYNCHRONIZE-2 (adults with type 2 diabetes) and SYNCHRONIZE-MASLD are part of the obesity programme [2].
- Liver disease: LIVERAGE and LIVERAGE-Cirrhosis are testing survodutide in MASH with fibrosis and in compensated MASH cirrhosis [2].
- Women's health and real-world use: SYNCHRONIZE-HERA and SYNCHRONIZE-START are planned phase IIIb studies [2].
- Regulator conversations: Balachander told Fierce that timing is "a conversation with the regulators" [4].
Until a regulator decides, Boehringer's statement that survodutide "has not been approved for use" stands [2]. How AI tools in medicine are evaluated and regulated is covered in AI in Healthcare: What It Can Do Today, Where It Fails and How It Is Regulated.
| Measure | Survodutide | Placebo | Source |
|---|---|---|---|
| Primary heart/stroke composite | 3.7% | 4.1% | [1] |
| Hazard ratio (95% CI) | 0.89 (0.67–1.18) | reference | [1] |
| Nausea | 48.0–49.0% | 12.1% | [1] |
| Stopped for digestive effects | 19.3–20.8% | 1.9% | [1] |
| Serious adverse events | 20.8–22.5% | 23.9% | [1] |
| Weight change at 72 weeks (supplementary estimand) | up to −13.7% | −2.0% | [2] |
Common mistakes
Saying survodutide cuts heart attacks
Fix: The trial showed no increase in risk; the CI includes no effect [1].
Thinking survodutide is approved
Fix: Boehringer says it has not been approved for use [2].
Quoting 13.7% as the typical result
Fix: That figure uses a supplementary estimand assuming continued treatment [2].
Ignoring tolerability
Fix: About 1 in 5 stopped because of digestive side effects [1].
Comparing directly with Zepbound or Wegovy
Fix: No head-to-head trial; Fierce cautions on cross-trial comparisons [4].
Frequently asked questions
What is survodutide?
An investigational weekly glucagon/GLP-1 dual agonist injection from Boehringer Ingelheim [2].
What did the SYNCHRONIZE-CVOT trial find?
Major heart events in 3.7% vs 4.1% on placebo; HR 0.89, meeting non-inferiority [1].
Does survodutide protect the heart?
The trial showed no increased risk, not a proven reduction [1].
Why do obesity drugs need heart safety trials?
The Lancet authors write that cardiovascular safety for this new drug class had not been established [1].
Who was in the survodutide trial?
5,530 randomised adults with BMI 27+ and heart, kidney or metabolic risks, in 34 countries [1].
What are the side effects of survodutide?
Mainly nausea and vomiting; about 1 in 5 stopped for digestive effects [1].
Glossary
- Glucagon/GLP-1 dual agonist
- A drug that activates both glucagon and GLP-1 hormone receptors.
- CVOT
- Cardiovascular outcomes trial, testing a drug's effect on heart events.
- MACE
- Major adverse cardiovascular events, such as heart attack, stroke or cardiovascular death.
- Non-inferiority
- A design showing a treatment is not worse than a comparator by more than a set margin.
- Hazard ratio
- The relative rate of an event in one group versus another over time.
- Estimand
- A precise definition of the treatment effect a trial analysis estimates.
Sources
- Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT) The Lancet · 2026-11-09
- Survodutide demonstrates favorable cardiovascular safety profile in SYNCHRONIZE-CVOT Boehringer Ingelheim (GlobeNewswire) · 2026-11-09
- SYNCHRONIZE-CVOT (NCT06077864) ClinicalTrials.gov · 2026-11-12
- AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test Fierce Biotech · 2026-11-09
- Obesity and overweight World Health Organization · 2026-10-07
Comments
Top comments